Rani Therapeutics Holdings, Inc. (RANI) stock
RANINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 2/3044% above fair value
$0.53+0.00 (+0.21%)
Close on Nov 13, 2026Market cap $73.36MP/E –Yield –
Rani Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Rani Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$34.30M. For fiscal 2025 it was -$37.41M. The highest annual figure on record is -$37.41M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$37.41M | – |
| FY2024 | Dec 31, 2024 | -$52.29M | – |
| FY2023 | Dec 31, 2023 | -$65.28M | – |
| FY2022 | Dec 31, 2022 | -$62.90M | – |
| FY2021 | Dec 31, 2021 | -$51.10M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$9.10M | – |
| Q2 FY2026 | Jun 30, 2026 | -$8.68M | – |
| Q1 FY2026 | Mar 31, 2026 | -$8.18M | – |
| Q4 FY2025 | Dec 31, 2025 | -$8.35M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.03M | – |
| Q2 FY2025 | Jun 30, 2025 | -$10.27M | – |
| Q1 FY2025 | Mar 31, 2025 | -$11.76M | – |
| Q4 FY2024 | Dec 31, 2024 | -$14.69M | – |
| Q3 FY2024 | Sep 30, 2024 | -$11.54M | – |
| Q2 FY2024 | Jun 30, 2024 | -$12.27M | – |
| Q1 FY2024 | Mar 31, 2024 | -$13.79M | – |
| Q4 FY2023 | Dec 31, 2023 | -$13.21M | – |
| Q3 FY2023 | Sep 30, 2023 | -$17.64M | – |
| Q2 FY2023 | Jun 30, 2023 | -$18.11M | – |
| Q1 FY2023 | Mar 31, 2023 | -$16.33M | – |
| Q4 FY2022 | Dec 31, 2022 | -$17.31M | – |
| Q3 FY2022 | Sep 30, 2022 | -$16.20M | – |
| Q2 FY2022 | Jun 30, 2022 | -$15.73M | – |
| Q1 FY2022 | Mar 31, 2022 | -$13.67M | – |
| Q4 FY2021 | Dec 31, 2021 | -$13.25M | – |
| Q3 FY2021 | Sep 30, 2021 | -$27.66M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.68M | – |
See a number that looks wrong?